NDRG4 methylation in blood leukocytes associated with gastric cancer risk and prognosis in a case-control study.

This case-control study investigated the methylation of the NDRG4 gene in peripheral blood leukocytes within a population comprising 310 gastric cancer patients and 300 controls. The study design involved comparing these groups to assess associations with gastric cancer risk, chemotherapy efficacy, and overall prognosis. Additionally, secondary outcomes included the expression of NDRG family genes, immune-related signatures, and various methylation patterns.

The analysis focused on 280 gastric cancer patients specifically for SNP analysis, comparing the hypomethylation group and different rs7202037 genotypes against controls. The study aimed to determine if methylation patterns serve as markers for disease status or treatment response. However, the main results section of the abstract text is truncated, meaning specific numerical data, p-values, or confidence intervals regarding these associations are not reported in the available information.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. Similarly, funding sources and potential conflicts of interest are not reported. The study notes that causality was analyzed as an association, and the certainty of the findings is limited because the abstract text is incomplete and results are not fully reported.

Given the incomplete reporting of results and the observational nature of the case-control design, the clinical relevance for current practice cannot be determined from this text. Clinicians should interpret these preliminary associations with caution until full data and validation are available.